NFE2L2 and esophageal squamous cell carcinoma: Notably, previous studies have verified that knockdown of NFE2L2 promotes the proliferation of ESCC cells,3 indicating poorer patient prognosis, which aligns with the chromosome 2 deletions observed in our cohort at stages III–IV.